Evidence map›Paper›PMID 32686260›Full record

ReviewCytometry. Part A : the journal of the International Society for Analytical Cytology2020

Insights in Chloroquine Action: Perspectives and Implications in Malaria and COVID-19.

Micheli Mainardi Pillat, Arne Krüger, Lara Mendes Ferreira Guimarães, Claudiana Lameu, Edmarcia Elisa de Souza, Carsten Wrenger, Henning Ulrich

Open access · bronzeAbstract readReview
In one paragraph

Review in Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.2field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Micheli Mainardi Pillat *Department of Microbiology and Parasitology, Health Sciences Center, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brazil.
Arne Krüger *Department of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-5531-9508
Lara Mendes Ferreira GuimarãesDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Claudiana LameuDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.
Edmarcia Elisa de SouzaDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.
Carsten WrengerDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.ORCID 0000-0001-5987-1749
Henning UlrichDepartment of Biochemistry, Institute of Chemistry, University of São Paulo, São Paulo, Brazil.ORCID 0000-0002-2114-3815
Universidade de São Paulo · BRUniversidade Federal de Santa Maria · BR

Funding

Conselho Nacional de Desenvolvimento Científico e TecnológicoCoordenação de Aperfeiçoamento de Pessoal de Nível SuperiorFundação de Amparo à Pesquisa do Estado de São Paulo 2015/19128-2Fundação de Amparo à Pesquisa do Estado de São Paulo 2015/26722-8Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/07366-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2018/08820-0Fundação de Amparo à Pesquisa do Estado do Rio Grande do SulSão Paulo Research Foundation
6 · The paper itself

Abstract

Malaria is a threat to human mankind and kills about half a million people every year. On the other hand, COVID-19 resulted in several hundred thousand deaths since December 2019 and remains without an efficient and safe treatment. The antimalarials chloroquine (CQ) and its analog, hydroxychloroquine (HCQ), have been tested for COVID-19 treatment, and several conflicting evidence has been obtained. Therefore, the aim of this review was to summarize the evidence regarding action mechanisms of these compounds against Plasmodium and SARS-CoV-2 infection, together with cytometry applications. CQ and HCQ act on the renin angiotensin system, with possible implications on the cardiorespiratory system. In this context, flow and image cytometry emerge as powerful technologies to investigate the mechanism of therapeutic candidates, as well as for the identification of the immune response and prognostics of disease severity. Data from the large randomized trials support the conclusion that CQ and HCQ do not provide any clinical improvements in disease severity and progression of SARS-CoV-2 patients, as well as they do not present any solid evidence of increased serious side effects. These drugs are safe and effective antimalarials agents, but in SARS-CoV-2 patients, they need further studies in the context of clinical trials. © 2020 International Society for Advancement of Cytometry.

Indexed as

AnimalsAntimalarialsAntiviral AgentsBetacoronavirusChloroquineCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentFlow CytometryHost Microbial InteractionsHost-Parasite InteractionsHumansMalariaPandemicsPlasmodiumPneumonia, ViralAntimalarialsAntiviral AgentsChloroquineautophagyclinical trialsPlasmodiumrenin angiotensin systemSARS-CoV-2side effectviral invasion

Identifiers

PMID32686260
PMCPMC7404934
OpenAlexW3043206575

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.